Will melatonin supplementation become a new form of obesity treatment? A review of recent literature.
Open Access
- 20 September 2024
- journal article
- review article
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 22, 54679
Abstract
Background: In 2020, the World Health Organization (WHO) estimated that 650 million adults worldwide are obese, and 2.8 billion individuals struggle with overweight. Obesity is associated with an increased risk of cardiovascular diseases, type 2 diabetes, heart disease, adverse effects on mental health, the development of certain cancers, and other conditions. In recent years, there has been growing interest in the role of melatonin, which has therapeutic potential in the treatment of obesity. Studies suggest that melatonin supplementation may lead to weight reduction and improvement in metabolic parameters, significantly reduce cardiovascular disease risk factors, and enhance insulin sensitivity in obese individuals. Aim of study: This review aims to present the latest scientific findings on the impact of melatonin supplementation on the development of obesity and its complications. We focus primarily on the mechanisms of melatonin's action in the context of obesity, particularly on potential pathways that have not yet been thoroughly explored. Our aim is to provide deeper insights into research on obesity and its prevention. Materials and Methods: Search was conducted using PubMed and Google Scholar databases, utilizing the keywords "obesity," "melatonin," and "weight loss" in various configurations. The review primarily considers studies published after 2016 that are available online. Summary Melatonin supplementation leads to a statistically significant reduction in blood glucose levels and an increase in cellular insulin sensitivity. Its promising properties in the treatment of obesity have been demonstrated through the reduction of oxidative stress, indicating a potential adjunct for weight loss. Based on the cited studies, the beneficial effects of melatonin supplementation on cardiovascular risk factors have been confirmed. Melatonin could be considered as an adjunctive therapy for obese individuals who do not respond to other treatment modalities.Keywords
This publication has 32 references indexed in Scilit:
- Cisplatin's dual-effect on the circadian clock triggers proliferation and apoptosisNeurobiology of Sleep and Circadian Rhythms, 2020
- Melatonin suppresses chronic restraint stress-mediated metastasis of epithelial ovarian cancer via NE/AKT/β-catenin/SLUG axisCell Death & Disease, 2020
- Melatonin, an ubiquitous metabolic regulator: functions, mechanisms and effects on circadian disruption and degenerative diseasesReviews in Endocrine and Metabolic Disorders, 2020
- Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant CancersCancer Cell, 2020
- Melatonin mediates mucosal immune cells, microbial metabolism, and rhythm crosstalk: A therapeutic target to reduce intestinal inflammationMedicinal Research Reviews, 2019
- The epidemiology of obesityMetabolism, 2019
- Humans against Obesity: Who Will Win?Advances in Nutrition, 2019
- Body Fatness and Cancer — Viewpoint of the IARC Working GroupNew England Journal of Medicine, 2016
- The Safety of Melatonin in HumansClinical Drug Investigation, 2015
- Melatonin directly scavenges hydrogen peroxide: a potentially new metabolic pathway of melatonin biotransformationFree Radical Biology and Medicine, 2000